Rigel Pharmaceuticals INC 8-K filings

Rigel Pharmaceuticals announced robust second quarter 2026 financial results, including record net product sales and net income, alongside the strategic in-license of VEPPANU.

Rigel Pharmaceuticals announced a change in its Chief Medical Officer role and a related board resignation, effective July 1, 2026.

Rigel Pharmaceuticals has finalized its exclusive global license agreement for VEPPANU (vepdegestrant) and related products, making an upfront payment of $70.0 million.

Rigel Pharmaceuticals stockholders approved amendments to equity and stock purchase plans, re-elected directors, and ratified auditor selection at the 2026 Annual Meeting.

Rigel Pharmaceuticals has entered into an exclusive worldwide license agreement with Arvinas and Pfizer to commercialize the breast cancer therapy VEPPANU.

Rigel Pharmaceuticals announced first quarter 2026 financial results, reporting $58.8 million in total revenues and $8.7 million in net income, while reaffirming its full-year revenue guidance.

Rigel Pharmaceuticals announced that Eli Lilly has terminated their 2021 license and collaboration agreement for RIPK1 inhibitors.

Rigel Pharmaceuticals announced record net product sales and net income for 2025, alongside positive financial guidance for 2026 and progress in its R289 clinical study.

Rigel Pharmaceuticals announced preliminary strong fourth quarter and full-year 2025 financial results, provided a positive 2026 outlook with anticipated profitability, and shared encouraging clinical updates across its pipeline.

Rigel Pharmaceuticals announced updated Phase 1b study data for R289 in lower-risk myelodysplastic syndrome, showing preliminary efficacy and good tolerability.

Rigel Pharmaceuticals reported robust third-quarter 2025 financial results, including record net product sales and a significant increase in net income, leading to an upward revision of its full-year 2025 revenue guidance.

Rigel Pharmaceuticals reported robust second-quarter 2025 financial results, including significant revenue growth and net income, leading to an upward revision of its full-year 2025 financial guidance.

Rigel Pharmaceuticals, Inc. announced that its stockholders approved an amendment to the 2018 Equity Incentive Plan, adding 700,000 shares, and elected two directors at its 2025 Annual Meeting.

Rigel Pharmaceuticals announces a profitable first quarter in 2025, driven by strong product sales and strategic collaborations, setting a positive outlook for the year.

Rigel Pharmaceuticals resolves patent litigation with Annora Pharma, allowing for a potential generic version of TAVALISSE to enter the market no earlier than Q2 2032.

Rigel Pharmaceuticals announced the appointment of Mark J. Frohlich to its board of directors, effective March 6, 2025.

Rigel Pharmaceuticals announces strong fourth quarter and full-year 2024 financial results, including record net product sales and the first full-year net income, alongside a positive outlook for 2025.

Rigel Pharmaceuticals reports strong preliminary Q4 2024 revenue and provides an optimistic financial outlook for 2025, including anticipated profitability.

Rigel Pharmaceuticals reported positive initial data from its Phase 1b trial of R289, showing clinical activity and tolerability in patients with lower-risk myelodysplastic syndrome.

Rigel Pharmaceuticals announced a profitable third quarter in 2024, driven by strong sales of its commercial products and a significant licensing agreement.

Dr. Brian Kotzin resigned from Rigel Pharmaceuticals' Board of Directors and related committees, effective September 16, 2024.

Rigel Pharmaceuticals has granted Kissei Pharmaceutical exclusive rights to develop and commercialize olutasidenib in Japan, South Korea, and Taiwan, securing an upfront payment and potential future milestones.

Rigel Pharmaceuticals announced its second quarter 2024 financial results, highlighted by record sales of TAVALISSE and REZLIDHIA, and the successful acquisition of GAVRETO.

Rigel Pharmaceuticals has completed a 1-for-10 reverse stock split, effective June 27, 2024, to increase its share price.

Rigel Pharmaceuticals will implement a 1-for-10 reverse stock split effective June 27, 2024, to increase its share price and maintain Nasdaq compliance.

Rigel Pharmaceuticals' stockholders approved an amended equity incentive plan, the election of two directors, and a reverse stock split proposal at their 2024 Annual Meeting.

Rigel Pharmaceuticals announced its first quarter 2024 financial results, highlighted by increased product sales and the acquisition of GAVRETO, a marketed cancer treatment.

Rigel Pharmaceuticals has amended its credit agreement with MidCap Financial, extending the loan maturity date to September 1, 2027, and modifying other key terms.

Rigel Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighted by increased product sales and the acquisition of U.S. rights to GAVRETO.

Rigel Pharmaceuticals has acquired the U.S. rights to pralsetinib, a RET inhibitor for cancer treatment, from Blueprint Medicines for an upfront payment of $15 million plus potential milestone and royalty payments.